Comparing Safety Profiles: Making Informed Treatment Decisions in mCRC

March 4, 2025

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA
Melody Chang, RPh, MBA, BCOP

Opinion

Video

Experts discuss how they balance safety, efficacy, and overall patient prognosis when selecting third-line treatments for metastatic colorectal cancer (mCRC) and explore how the toxicity profiles of fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab differ, informing treatment decisions.

EP: 1.Treatment Options in mCRC: A Clinical Overview

Now Viewing

EP: 2.Comparing Safety Profiles: Making Informed Treatment Decisions in mCRC

EP: 3.Quality of Life and Patient Outcomes in mCRC Treatment

EP: 4.Optimizing Treatment Sequencing in Advanced Colorectal Cancer

EP: 5.The Patient Journey: Mapping the Pharmacist’s Role in mCRC Management

EP: 6.Evolution of Oncology Pharmacy Practice in mCRC

EP: 7.Pharmacist-Led Strategies for Adverse Event Management in mCRC

EP: 8.Navigating Cost Considerations in Treatment Selection of mCRC Agents

EP: 9.Best Practices for Overcoming mCRC Prior Authorization Barriers

EP: 10.Building Better Collaboration: Reducing Care Delays in Managing mCRC

Video content above is prompted by the following:

When selecting third-line treatments for mCRC, how do you balance safety, efficacy, and overall patient prognosis?
How do the toxicity profiles of fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab differ, and how can these differences inform treatment decisions?